Martin BAUER    SITE

  • Front Pharmacol. 2021;12:698966. ABCB1 and ABCG2 together limit the distribution of ABCB1/ABCG2 substrates to the human retina and the ABCG2 Single Nucleotide Polymorphism Q141K (c.421C> A) may lead to increased drug exposure. El Biali M, Karch R, Philippe C, Haslacher H, Tournier N, Hacker M, Zeitlinger M, Schmidl D, Langer O, Bauer M. PubMed
  • Mol Imaging Biol. 2021;23:180-185. Human biodistribution and radiation dosimetry of the P-Glycoprotein radiotracer [11C]Metoclopramide. Bauer M, Barna S, Blaickner M, Prosenz K, Bamminger K, Pichler V, Tournier N, Hacker M, Zeitlinger M, Karanikas G, Langer O. PubMed
  • Clin Pharmacol Ther. 2021;109:754-761. Impaired clearance from the brain increases the brain exposure to metoclopramide in elderly subjects. Bauer M, Bamminger K, Pichler V, Weber M, Binder S, Maier-Salamon A, Tahir A, Jäger W, Haslacher H, Tournier N, Hacker M, Zeitlinger M, Langer O. PubMed
  • EJNMMI Res. 2019;9:110. Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography. Wulkersdorfer B, Bauer M, Karch R, Stefanits H, Philippe C, Weber M, Czech T, Menet MC, Declèves X, Hainfellner JA, Preusser M, Hacker M, Zeitlinger M, Müller M, Langer O. PubMed
  • J Nucl Med. 2020;61:1050-1057. Imaging P-glycoprotein induction at the Blood-Brain Barrier of a Beta-Amyloidosis mouse model with 11C-Metoclopramide PET. Zoufal V, Mairinger S, Brackhan M, Krohn M, Filip T, Sauberer M, Stanek J, Wanek T, Tournier N, Bauer M, Pahnke J, Langer O. PubMed
  • Mol Pharm. 2020;17:316-326. Measurement of hepatic ABCB1 and ABCG2 transport activity with [11C]Tariquidar and PET in humans and mice. Hernández Lozano I, Bauer M, Wulkersdorfer B, Traxl A, Philippe C, Weber M, Häusler S, Stieger B, Jäger W, Mairinger S, Wanek T, Hacker M, Zeitlinger M, Langer O. PubMed
  • J Nucl Med. 2020;61:306. Pharmacokinetic imaging with radiolabeled molecularly targeted anticancer drugs. Bauer M, Zeitlinger M, Langer O. PubMed
  • J Nucl Med. 2020 ;61:276-284. Promise of fully integrated PET/MRI: Noninvasive clinical quantification of cerebral glucose metabolism. Shiyam Sundar LK, Muzik O, Rischka L, Hahn A, Lanzenberger R, Hienert M, Klebermass EM, Bauer M, Rausch I, Pataraia E, Traub-Weidinger T, Beyer T. PubMed
  • AAPS J. 2019;21:61. Towards improved pharmacokinetic models for the analysis of transporter-mediated hepatic disposition of drug molecules with Positron Emission Tomography. Hernández Lozano I, Karch R, Bauer M, Blaickner M, Matsuda A, Wulkersdorfer B, Hacker M, Zeitlinger M, Langer O. PubMed
  • Mol Pharm. 2019;16:1282-1293. Inhibition of ABCB1 and ABCG2 at the mouse Blood-Brain Barrier with marketed drugs to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib. Traxl A, Mairinger S, Filip T, Sauberer M, Stanek J, Poschner S, Jäger W, Zoufal V, Novarino G, Tournier N, Bauer M, Wanek T, Langer O. PubMed
  • J Nucl Med. 2019;60:486-491. A proof-of-concept study to inhibit ABCG2- and ABCB1-mediated efflux transport at the human Blood-Brain Barrier. Bauer M, Karch R, Wulkersdorfer B, Philippe C, Nics L, Klebermass EM, Weber M, Poschner S, Haslacher H, Jäger W, Tournier N, Wadsak W, Hacker M, Zeitlinger M, Langer O. PubMed
  • Mol Pharm. 2018;15:4589-4598. Effect of rifampicin on the distribution of [11C]Erlotinib to the liver, a translational PET study in humans and in mice. Bauer M, Traxl A, Matsuda A, Karch R, Philippe C, Nics L, Klebermass EM, Wulkersdorfer B, Weber M, Poschner S, Tournier N, Jäger W, Wadsak W, Hacker M, Wanek T, Zeitlinger M, Langer O. PubMed
  • EJNMMI Res. 2018;8:81. Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats. Amor D, Goutal S, Marie S, Caillé F, Bauer M, Langer O, Auvity S, Tournier N. PubMed
  • J Nucl Med. 2018;59:1609-1615. P-Glycoprotein (ABCB1) inhibits the influx and increases the efflux of 11C-Metoclopramide across the Blood-Brain Barrier: A PET study on nonhuman primates. Auvity S, Caillé F, Marie S, Wimberley C, Bauer M, Langer O, Buvat I, Goutal S, Tournier N. PubMed
  • Eur J Drug Metab Pharmacokinet. 2018;43:599-606. Pharmacokinetics of the P-gp inhibitor Tariquidar in rats after intravenous, oral, and intraperitoneal administration. Matzneller P, Kussmann M, Eberl S, Maier-Salamon A, Jäger W, Bauer M, Langer O, Zeitlinger M, Poeppl W. PubMed
  • Clin Pharmacol Ther. 2018;104:139-147. Influence of OATPs on hepatic disposition of Erlotinib measured with Positron Emission Tomography. Bauer M, Matsuda A, Wulkersdorfer B, Philippe C, Traxl A, Özvegy-Laczka C, Stanek J, Nics L, Klebermass EM, Poschner S, Jäger W, Patik I, Bakos É, Szakács G, Wadsak W, Hacker M, Zeitlinger M, Langer O. PubMed
  • Br J Clin Pharmacol. 2017;83:1991-1999. Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[11 C]verapamil in elderly vs. young subjects. Bauer M, Wulkersdorfer B, Karch R, Philippe C, Jäger W, Stanek J, Wadsak W, Hacker M, Zeitlinger M, Langer O. PubMed
  • J Pharm Sci. 2017;106:2780-2786.  A prediction method for P-glycoprotein-mediated drug-drug interactions at the human blood-brain barrier from blood concentration-time profiles, validated with PET data. Matsuda A, Karch R, Bauer M, Traxl A, Zeitlinger M, Langer O. PubMed
  • J Nucl Med. 2017;58:678-681. Assessment of P-Glycoprotein transport activity at the human blood-retina barrier with (R)-11C-Verapamil PET. Bauer M, Karch R, Tournier N, Cisternino S, Wadsak W, Hacker M, Marhofer P, Zeitlinger M, Langer O. PubMed
  • Clin Pharmacol Ther. 2016;100:131-41. Pilot PET study to assess the functional interplay between ABCB1 and ABCG2 at the human blood-brain barrier. Bauer M, Römermann K, Karch R, Wulkersdorfer B, Stanek J, Philippe C, Maier-Salamon A, Haslacher H, Jungbauer C, Wadsak W, Jäger W, Löscher W, Hacker M, Zeitlinger M, Langer O. PubMed
  • J Cereb Blood Flow Metab. 2015;35:743-6. Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[11C]verapamil PET study. Bauer M, Karch R, Zeitlinger M, Philippe C, Römermann K, Stanek J, Maier-Salamon A, Wadsak W, Jäger W, Hacker M, Müller M, Langer O. PubMed
  • Neurology. 2014;83:1326-31. In vivo P-glycoprotein function before and after epilepsy surgery. Bauer M, Karch R, Zeitlinger M, Liu J, Koepp MJ, Asselin MC, Sisodiya SM, Hainfellner JA, Wadsak W, Mitterhauser M, Müller M, Pataraia E, Langer O. PubMed
  • Clin Pharmacol Ther. 2014;96:206-13. Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues. Wulkersdorfer B, Wanek T, Bauer M, Zeitlinger M, Müller M, Langer O. PubMed
  • J Nucl Med. 2013;54:1181-7. Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier. Bauer M, Karch R, Zeitlinger M, Stanek J, Philippe C, Wadsak W, Mitterhauser M, Jäger W, Haslacher H, Müller M, Langer O. PubMed
  • Pharmacology. 2013;91:12-9. Pharmacokinetics of single ascending doses of the P-glycoprotein inhibitor tariquidar in healthy subjects. Bauer M, Zeitlinger M, Todorut D, Böhmdorfer M, Müller M, Langer O, Jäger W. PubMed
  • Clin Pharmacol Ther. 2012;91:227-33. Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data. Bauer M, Zeitlinger M, Karch R, Matzneller P, Stanek J, Jäger W, Böhmdorfer M, Wadsak W, Mitterhauser M, Bankstahl JP, Löscher W, Koepp M, Kuntner C, Müller M, Langer O. PubMed
  • J Cereb Blood Flow Metab. 2010;30:510-5. Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier. Bauer M, Karch R, Neumann F, Wagner CC, Kletter K, Müller M, Löscher W, Zeitlinger M, Langer O. PubMed
  • J Nucl Med. 2009;50:1954-61. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET.Wagner CC, Bauer M, Karch R, Feurstein T, Kopp S, Chiba P, Kletter K, Löscher W, Müller M, Zeitlinger M, Langer O. PubMed
  • Eur J Clin Pharmacol. 2009;65:941-6. Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET. Bauer M1, Karch R, Neumann F, Abrahim A, Wagner CC, Kletter K, Müller M, Zeitlinger M, Langer O. PubMed
  • Epilepsia. 2007;48:1774-1784. Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. Langer O, Bauer M, Hammers A, Karch R, Pataraia E, Koepp MJ, Abrahim A, Luurtsema G, Brunner M, Sunder-Plassmann R, Zimprich F, Joukhadar C, Gentzsch S, Dudczak R, Kletter K, Müller M, Baumgartner C. PubMed

PubMed

Vienna, Austria

BAUER MARTIN.jpg

Last update: August 2021